OrbiMed’s AstraZeneca AZN Stock Holding History

OrbiMed’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-125,000	Closed	-$8.52M	–	145
2017 Q2	$8.52M	Buy	+125,000	New	+$8.16M	0.09%	102

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

OrbiMed's AZN Position: Q1 2026 in Review

OrbiMed opened a new position in AstraZeneca (AZN) in Q1 2026: 670,200 shares worth $132M. The stake represents 2.62% of the portfolio and ranks #9 among its holdings. This is a return to the name: OrbiMed previously reported a position in AZN as recently as Q4 2019.

OrbiMed first reported a position in AZN in Q4 2019 and has held it in 2 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

OrbiMed held 670,200 shares of AstraZeneca worth $132M as of Q1 2026.
AstraZeneca was a new OrbiMed position in Q1 2026.
AstraZeneca made up 2.62% of OrbiMed's portfolio in Q1 2026, its #9 holding.
OrbiMed first reported a position in AstraZeneca in Q4 2019 and has held it in 2 quarters since.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.